Sort   by:  
 Page size 
This is a class prediction experiment, where the class is the response status to imatinib (also called Gleevec), a drug used to treat patients with chronic myelogenous leukemia (CML). There are two data sets, a training set (from Leipzig, 8 Responders and 5 Non-Responders) and a validation set (fro...
ORGANISM(S): Homo sapiens 
Oligonucleotide expression microarray data used for expression signature associated with WT1 mutations in cytogenetically normal AML patient samples
ORGANISM(S): Homo sapiens 
To identify cooperating lesions in core-binding-factor acute myeloid leukemia (CBF-AML), we performed single-nucleotide polymorphism (SNP)-array analysis on 300 diagnostic and 41 relapse adult and pediatric leukemia samples. We identified a mean of 1.28 copy number alterations (CNAs) per case at dia...
ORGANISM(S): Homo sapiens 
Core binding factor (CBF) leukemias, characterized by translocations t(8;21) or inv(16)/t(16;16) targeting the core binding factor, constitute acute myeloid leukemia (AML) subgroups with favorable prognosis. However, about 40% of patients relapse, and the current classification system does not fully...
ORGANISM(S): Homo sapiens 
microRNA microarray data used for analysis of miR-29b expression in AML patient samples
ORGANISM(S): Homo sapiens 
Oligonucleotide expression microarray data used for analysis of KIT and SP1 expression levels in AML patient samples
ORGANISM(S): Homo sapiens 
To identify cooperating lesions in de novo and therapy-related acute myeloid leukemia (t-AML) with translocation t(9;11)(p22;q23) we performed high-resolution SNP-array profiling on 40 leukemia samples [de novo: n=22; t-AML: n=16; unknown: n=2]. A mean of 1.73 copy number alterations (CNAs)/case wer...
ORGANISM(S): Homo sapiens 
Sort   by:  
 Page size